VitaNova Life Sciences (VNOV) Cost of Revenue (2017 - 2026)

VitaNova Life Sciences has disclosed Cost of Revenue across 4 years of filings, most recently posting $291055.0 for Q3 2026.

• Cost of Revenue for Q3 2026 came in at $291055.0, up 728.79% year-over-year; the trailing twelve-month figure through Jul 2026 was $2.4 million (up 118.27% YoY), and the FY2026 annual result was $2.1 million, up 94.68% from the prior year.
• Cost of Revenue for Q3 2026 stood at $291055.0, down from $1.5 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $1.5 million in Q2 2026 and bottomed at $35118.0 in Q3 2025.
• Average Cost of Revenue over 3 years is $368538.2, with a median of $179647.5 recorded in 2024.
• The widest annual swing landed in 2025, when Cost of Revenue slipped 0.53%; it then soared 728.79% in 2026.
• Year by year, Cost of Revenue stood at $136284.0 in 2024, then increased by 22.03% to $166312.0 in 2025, then jumped by 75.01% to $291055.0 in 2026.
• The last three Cost of Revenue figures came in at $291055.0 (Q3 2026), $1.5 million (Q2 2026), and $393282.0 (Q1 2026), per Business Quant data.